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TO THE EDITOR
In recent years, a regulatory role has
emerged for the glycan-binding protein
galectin-9 (Gal-9) in normal physiology
and pathology (reviewed by Wiersma
et al. (2011). In melanoma and other
malignancies, the available data suggest
that Gal-9 has a tumor-suppressor func-
tion, with loss of Gal-9 being closely
associated with metastatic progression
(Kageshita et al., 2002; Irie et al., 2005;
Yamauchi et al., 2006; Liang et al.,
2008). In particular, melanocytic nevi
and primary melanoma lesions highly
express Gal-9, whereas metastatic mel-
anoma lesions have no or minimal
expression of Gal-9 (Kageshita et al.,
2002). Furthermore, ectopic expression
of Gal-9 abrogates the formation of
metastases by Gal-9-deficient B16F10
murine melanoma cells (Nobumoto
et al., 2008). Similarly, treatment of
Gal-9-deficient B16F10 cells with a
recombinant form of Gal-9, designated
Gal-9(0), strongly reduced metastasis
formation (Nobumoto et al., 2008).
This anti-metastatic activity of Gal-9(0)
on B16F10 has been attributed mainly
to inhibition of melanoma cell adhesion
to endothelial cells and/or extracellular
matrix components, such as collagen
type I (collagen-I; Nobumoto et al.,
2008). The data presented in the current
letter suggest that within the 1-h time
frame of adhesion-type assays, treat-
ment with Gal-9(0) triggers early apop-
totic cellular changes. In line with earlier
findings, Gal-9(0) inhibits the adhesion
of B16F10 and 7 human melanoma cell
lines to collagen-I (Figure 1a). However,
the morphology of Gal-9(0)-treated cells
that had adhered to collagen-I-coated
wells resembled that of dying cells
(Figure 1b; illustrated for B16F10).
Subsequent analysis of this melanoma
cell line panel, as well as primary patient–-
derived malignant melanoma cells for
the early apoptotic marker phosphatidyl
serine (PS), revealed that treatment with
Gal-9(0) inducedB90% cell death with-
in the time frame used in the adhesion
assay (Figure 1c). Early apoptotic PS
exposure was followed by apoptotic
cell death within 24 h of treatment, as
evidenced by loss of viability (Supple-
mentary Figure S1a online), the presence
of late apoptotic Annexin-V/PI double-
positive cells (Supplementary Figure S1b
and c online), and an increase
in DNA fragmentation (Supplementary
Figure S1d online). In primary human
melanocytes, Gal-9(0) also triggered
PS exposure, albeit to a lesser extent
(Figure 1c; B55%). More importantly,
the viability of these normal cells was
not negatively affected after 24 h (Sup-
plementary Figure S1a online). Thus,
Gal-9(0) induces rapid apoptotic cell
death in melanoma cells, but not inAbbreviations: collagen-I, collagen type I; Gal-9, galectin-9; PS, phosphatidyl serine
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normal human melanocytes. PS expo-
sure induced by Gal-9(0) was fully
dependent on the glycan-binding spe-
cificity of Gal-9(0), as it was selectively
blocked by the competitive Gal-9
inhibitor alpha-lactose but not by the
irrelevant carbohydrate sucrose (Figure
1d). Sensitivity to Gal-9(0) did not or
only weakly correlated with expression
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Figure 1. Galectin-9 (Gal-9(0)) rapidly induces apoptosis in serum-free conditions. (a). Adhesion of B16F10 and a panel of human melanoma cell lines to
collagen-I-coated wells is inhibited by recombinant Gal-9. In brief, 3 104 melanoma cells were added to collagen-I-coated plates and incubated for 1 h at
37 1C in the presence or absence of 100 nM Gal-9(0). Subsequently, wells were washed twice with phosphate-buffered saline, and the number of adhered
cells was counted in three wells per condition. Experiments were performed in triplicates. (b) Light microscopic pictures of B16F10 cells adhered to
collagen-I-coated wells in untreated conditions and upon treatment with 100 nM Gal-9(0). Bar¼ 100mm. (c) Cells were treated for 1 h with 100 nM Gal-9(0) and
subsequently analyzed for the early apoptotic event of phosphatidyl serine (PS) exposure using flow cytometric Annexin-V-FITC staining. The following cells
were analyzed: B16F10, A2058, Sk-MEL-28, MM-RU, MM-WK, MM-AN, MM-EP, A375M, primary (prim.) patient–derived melanoma cells (n¼ 1), and
primary human melanocytes (n¼ 1). (d) B16F10, Sk-MEL-28, A2058, and MM-RU were treated with Gal-9(0) with or without alpha-lactose or sucrose.
(e) Sk-MEL-28, A2058, A375M, MM-AN, and MM-RU were treated with 100 nM Gal-9(0) for 5, 10, 15, and 20minutes. Graph represents the average PS
exposure detected in all five cell lines from three separate experiments. (f) MM-RU cells were treated with various Gal-9(0) concentrations (ranging from 5
to 200 nM), after which cells were simultaneously assessed for collagen-I adhesion and PS exposure. Statistical analysis was performed by linear regression,
yielding an r2 of 0.6497. In all cell death assays, cell death was assessed by flow cytometry using Annexin-V-FITC, which measures the early apoptotic exposure
of PS on the outer leaflet of the cell membrane.
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of endogenous Gal-9 (Supplementary
Figure S2 online; r2¼0.250). Time-
course analysis in five of the human
melanoma cell lines demonstrated that
treatment with Gal-9(0) induced PS
exposure in 460% of melanoma cells
within 5minutes of treatment (Figure 1e).
Furthermore, the extent of PS exposure
closely correlated with the inhibitory
effect of Gal-9(0) on collagen I binding
(Figure 1f, MM-RU; r2¼ 0.693). Together,
these data suggest that the biological
effect of Gal-9(0) in adhesion assays is
mediated, at least partly, through the
induction of cell death. It is noteworthy
that pan-caspase inhibition failed to
block the anti-adhesive and apoptotic
activity of Gal-9(0; Supplementary Fig-
ure S1e and f online). Thus, Gal-9(0)-
mediated melanoma apoptosis does
not require caspase activation, which
is in line with e.g. reports on gal-1-
mediated cell death of T cells (Hahn
et al., 2004).
Adhesion assays are typically per-
formed in serum-free conditions, whereas
in normal physiological situations the
presence of serum and/or plasma com-
ponents may affect the biological activity
of Gal-9. Indeed, it is well established
that Gal-9 can interact with serum com-
ponents (Cederfur et al., 2008). There-
fore, the biological activity of Gal-9(0)
was next evaluated in the presence of
10% fetal calf serum (FCS), the standard
serum additive in cell death assays. The
inclusion of 10% FCS in these apoptosis
experiments completely abrogated the
morphological changes in melanoma
cells, with induction of PS exposure by
Gal-9(0) being abrogated in six of the
seven cell lines tested (Figure 2a).
Similarly, PS exposure by Gal-9(0) was
also strongly inhibited in the primary
melanoma cells (Figure 2a). Indeed, FCS
dose dependently inhibited PS exposure
induced by Gal-9(0) (illustrated for cell
line A2058 in Figure 2b) and blocked
the binding of Gal-9(0) to A2058 cells
(Figure 2c). When using dialysed FCS or
heat-inactivated FCS, the activity of
Gal-9(0) was still inhibited (Figure 2d).
Thus, the inhibitory component present
in FCS is not heat labile (i.e., comple-
ment factors) and is 410 kDa in size.
Notably, FCS did not inhibit Gal-9(0)
activity toward SK-MEL-28 cells
(Figure 2a), which suggests that the
inhibitory effect of FCS is not merely
due to binding of a serum component
to Gal-9(0). Possibly, a serum compo-
nent may shield the receptor(s) of Gal-9
on most melanoma cells. On Sk-MEL-
28 cells, Gal-9(0) may interact with an
alternative receptor not subject to
binding/inhibition by FCS.
Although FCS is the standard addi-
tive in in vitro cell death assays, a better
approximation of physiological settings
is the addition of human plasma.
Importantly, 10% human pooled plas-
ma did not abrogate Gal-9(0)-induced
PS exposure in A2058 cells, with only
a slight reduction in PS exposure
compared with serum-free conditions
(Figure 2d). Similar results were ob-
tained in six melanoma cell lines and
in primary patient–derived melanoma
cells (Figure 2e).
These experiments suggest that an
important biological effect of Gal-9(0)
on human melanoma cells is the
induction of apoptosis. This biological
effect of Gal-9(0) is masked by as yet
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Figure 2. Cell death induction by galectin-9 (Gal-9(0)) is blocked by fetal calf serum (FCS) but not
by human pooled plasma. (a) A panel of melanoma cells and primary patient–derived melanoma cells
(n¼1) were treated for 1 h with Gal-9(0) in standard cell death conditions (with 10% FCS). (b) A2058
cells were treated with 100 nM Gal-9(0) in the presence of increasing concentrations of FCS and analyzed
for the percentage of cells with phosphatidyl serine (PS) exposure. (c) A2058 cells were incubated on
ice with 100 nM biotinylated Gal-9(0) in the presence of increasing concentrations of FCS. Cell surface
binding of Gal-9(0)-biotin was evaluated using Streptavidin-Alexa488 by flow cytometry. (d) A2058 cells
were treated with 100 nM Gal-9(0) in serum-free (SF) conditions or in the presence of 10% FCS, 10%
dialyzed FCS (dFCS), heat-inactivated FCS (hiFCS), or human pooled plasma (HPP). (e) A panel of
melanoma cell lines and primary patient–derived melanoma cells (n¼ 1) were treated with 100 nM
Gal-9(0) in SF conditions or in the presence of 10% HPP. In all assays, cell death was assessed by
flow cytometry using Annexin-V (AnneV)-FITC. All experiments were performed in triplicates.
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unidentified components present in
FCS, but is unmasked in serum-free
conditions or when human plasma is
used. Indeed, in standard FCS-contain-
ing culture conditions, apoptotic cell
death of the melanoma cell line MM-
RU was only detected after 72 h of
treatment with Gal-9 (Kageshita et al.,
2002). The use of FCS may similarly
mask the biological activity of other gal
family members. In this respect, gal-2,
-3, -4, and -8 interact with various serum
components (Cederfur et al., 2008).
Notably, plasma levels of several of
the gal family members are increased in
malignancy (Barrow et al., 2011). The
use of human pooled serum/plasma
instead of FCS for in vitro biological
assays with members of the Gal family
therefore appears prudent.
In conclusion, recombinant Gal-9
has a hitherto unrecognized cytotoxic
effect toward human melanoma cells,
which further highlights its potential
therapeutic applicability for the treat-
ment of human metastatic melanoma.
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